118 related articles for article (PubMed ID: 10898111)
1. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.
Paulussen A; Lavrijsen K; Bohets H; Hendrickx J; Verhasselt P; Luyten W; Konings F; Armstrong M
Pharmacogenetics; 2000 Jul; 10(5):415-24. PubMed ID: 10898111
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
3. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
4. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
5. Bimodal distribution of renal cytochrome P450 3A activity in humans.
Haehner BD; Gorski JC; Vandenbranden M; Wrighton SA; Janardan SK; Watkins PB; Hall SD
Mol Pharmacol; 1996 Jul; 50(1):52-9. PubMed ID: 8700118
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 3A expression in the human fetal liver: evidence that CYP3A5 is expressed in only a limited number of fetal livers.
Hakkola J; Raunio H; Purkunen R; Saarikoski S; Vähäkangas K; Pelkonen O; Edwards RJ; Boobis AR; Pasanen M
Biol Neonate; 2001; 80(3):193-201. PubMed ID: 11585982
[TBL] [Abstract][Full Text] [Related]
7. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
[TBL] [Abstract][Full Text] [Related]
8. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
9. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
[TBL] [Abstract][Full Text] [Related]
10. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
12. The genetic determinants of the CYP3A5 polymorphism.
Hustert E; Haberl M; Burk O; Wolbold R; He YQ; Klein K; Nuessler AC; Neuhaus P; Klattig J; Eiselt R; Koch I; Zibat A; Brockmöller J; Halpert JR; Zanger UM; Wojnowski L
Pharmacogenetics; 2001 Dec; 11(9):773-9. PubMed ID: 11740341
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
14. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
15. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
17. Variability in Expression of CYP3A5 in Human Fetal Liver.
Vyhlidal CA; Pearce RE; Gaedigk R; Calamia JC; Shuster DL; Thummel KE; Leeder JS
Drug Metab Dispos; 2015 Aug; 43(8):1286-93. PubMed ID: 25979262
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP.
Hamzeiy H; Vahdati-Mashhadian N; Edwards HJ; Goldfarb PS
Mutat Res; 2002 Mar; 500(1-2):103-10. PubMed ID: 11890939
[TBL] [Abstract][Full Text] [Related]
20. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
Miyazawa M; Shindo M; Shimada T
Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]